Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

90 results about "Buffy coat" patented technology

The buffy coat is the fraction of an anticoagulated blood sample that contains most of the white blood cells and platelets following density gradient centrifugation of the blood.

Buffy coat tube and float system and method

A tube and float system for use in separation and axial expansion of the buffy coat is provided. The system includes a transparent, or semi-transparent, flexible sample tube and a rigid separator float having a specific gravity intermediate that of red blood cells and plasma. The sample tube has an elongated sidewall having a first cross-sectional inner diameter. The float consists of a main body portion and one or more support members protruding from the main body portion to engage and support the sidewall of the sample tube. The main body portion and the support members of the float have a cross-sectional diameter less than that of the first cross-sectional inner diameter of the tube when the sample tube is expanded, such as by centrifugation. The main body portion of the float together with an axially aligned portion of the sidewall define an annular volume therebetween. The support members protruding from the main body portion of the float traverse said annular volume to produce one or more analysis areas. During centrifugation, the centrifugal force enlarges the diameter of the tube to permit density-based axial movement of the float in the tube. Thereafter, the centrifugal force is reduced to cause the tube sidewall to return to its first diameter, thereby capturing the float and trapping the buffy coat constituents in the analysis area. The buffy coat constituents can then be evaluated or measured.
Owner:BATTELLE MEMORIAL INST

Centrifuge comprising a blood bag system with an upper and lower outlet

The invention relates to a centrifuge provided with a blood bag system having an upper and lower outlet for separation of blood constituents, containing a rotor which can be driven in a rotative manner about a hub, wherein at least one conventional whole blood bag equipped with an upper outlet and with a lower outlet can be positioned vertically in this blood bag, while the whole blood bag can be arranged on the rotor in such a way that one outlet of the whole blood bag is bent in a radial direction, and the opposite outlet of the whole blood bag is bent in the other radial direction, so that the entire whole blood bag and the outlets thereof adopt an approximately Z- or S-shaped form in its functional position. In this case it is preferred that the upper outlet of the whole blood bag lie radially toward the interior and the lower outlet of the whole blood bag lie radially toward the exterior of the whole blood bag. The whole blood bag is held in an insert, and the insert is in its turn held by an approximately sector-shaped cartridge, wherein a plurality of such cartridges is uniformly distributed by being arranged around the circumference of the rotor. One advantage of the centrifuge is that conventional blood bags can be used and recovery of individual blood constituents (plasma, erythrocytes, buffycoat) can be achieved with a significantly higher degree of efficiency and functionality, and with a high degree of purity.
Owner:ANDREAS HETTICH GMBH & CO KG

Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood

A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence of target cells which have expressed surface epitopes that indicate intracellular infection by various viruses or other infectious agents, and also cells which have expressed surface epitopes that indicate the presence of non-infectious medical conditions. The analysis involves the examination of cells in the blood sample for the presence or absence of particular surface epitopes while the blood sample is disposed in a centrifuged blood sampling container. The epitopic analysis for the presence or absence of infected cells, or cells which indicate the presence of non-infectious medical conditions relies on the detection of known target expressed epitopes. The target epitopes on the target cell types are epitopes which are also known to be absent on normal circulating cells in the blood. Fluorophores or other labels with distinct wavelength emissions are coupled with specific binding agents such as lectins, antibodies, aptamers, or the like, which are directed against the target expressed epitopes. The epitopic analyses may be performed in or near the expanded buffy coat layer in the centrifuged blood sample. The epitopic analysis may be performed under magnification either visually and/or photometrically. The blood sampling container is sized to hold between about 1 and about 20 ml, preferably about 10 ml of blood, and contains an insert that occupies about 90-98% of the volume of the container bore in the area of the container where the target cells will, if present, be detected. The insert forces the target cells in question to reside in an annular space in the container which is adjacent to the circumference of the container bore. The entire analysis can be performed in a relatively short period of time which is typically a matter of minutes to single digit hours.
Owner:LEVINE ROBERT A +1

Non-animal source cell blood serum substitute and use thereof

The invention provides a non-animal origin cell cultivating serum substitute (PLT) and applications thereof. The PLT is prepared by the following method: 3 to 5 volume units of O-typed buffy coats and 1 volume unit of AB-typed plasma are mixed; 300 to 400 grams of the mixture is centrifuged; a supernatant is extracted as 1 volume unit of platelet-rich plasma; the platelet-rich plasma is filtered so as to remove leucocyte, stored under cryopreservation at the temperature below minus 10 DEG C for standby, and unfrozen at the temperature of 30 to 37 DEG C before use, and 3000 to 5000 grams of the platelet-rich plasma is centrifuged so as to remove platelet membrane fragments, thus obtaining the non-animal origin cell cultivating serum substitute. The non-animal origin cell cultivating serum substitute has following essential advantages: the PLT can be used as fetal bovine serum substitute in cell cultivation, thus avoiding animal-origin ingredients in cell cultivation, quickening cell multiplication and consequently satisfying the requirements of clinical security and operation period shortening, and the non-animal origin cell cultivating serum substitute is applicable not only to mesenchymal stem cells, but also to the multiplication cultivation of other human origin cells.
Owner:ZHEJIANG UNIV

Placental hematopoietic stem cell and preparation method thereof and placental hematopoietic stem cell injection

The invention relates to the field of biology and discloses a placental hematopoietic stem cell and a preparation method thereof and a placental hematopoietic stem cell injection. The preparation method comprises the following steps of: after pretreating a placenta, digesting the treated placenta by using collagenase type IV digestive juice and collagenase type II digestive juice, then washing and filtering and respectively collecting first filtrate and first residue; digesting the first filter residue by using collagenase type I digestive juice and the collagenase type II digestive juice in the first step and then washing, filtering and collecting second filtrate; combining the filtrate from two times, centrifuging and discarding supernate, re-suspending and precipitating; adding a resuspension solution into a lymphocytes separation medium; and carrying out density gradient centrifugation, collecting a buffy coat cell solution on an intermediate layer and centrifuging and discarding supernate to obtain the placental hematopoietic stem cell. According to the placental hematopoietic stem cell and the preparation method thereof disclosed by the invention, collagenase type IV and collagenase type II are combined, collagenase type I and collagenase type II are combined and the hematopoietic stem cell is prepared by fully digesting the placenta according to the characteristics of different collagenases, so that the quantity and the vitality of the prepared hematopoietic stem cell are improved.
Owner:BOYALIFE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products